These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|---|---|---|
Career Highlights : Ms. Nova has extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics. Ms. Nova spent 15 years as the co-founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co-founded a number of early-stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc. Key Expertise Provided to the Board : Ms. Nova is an industry veteran in life sciences, with experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts and brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, sold to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011. | |||
Career Highlights: Dr. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. Dr. Madaus has notable experience in strategy, mergers and acquisitions, and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG). Key Expertise Provided to the Board : As an experienced public company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, Dr. Madaus brings valuable operational insight and industry expertise to the Azenta Board and a proven track record of creating shareholder value in both public and private life science companies. | |||
Erica J. McLaughlin | Age 48 | (Director since April 2020) | |||
Career Highlights : Mr. Malus formerly served as Corporate Executive Vice President of Thermo Fisher. Prior, Mr. Malus served as President, Laboratory Products and Services at Thermo Fisher. He has held various leadership positions and senior executive positions in finance, marketing, commercial development, and operations since joining Thermo Fisher in 1998. Previously, Mr. Malus served as an independent director at PHC Holdings Corp., a global healthcare company, headquartered in Japan. Key Expertise Provided to the Board : Mr. Malus brings over 18 years of broad-reaching executive and operating experience in the life sciences and diagnostics industry. Mr. Malus also has global healthcare experience, with experience in enhancing growth strategies and market expansion. |
|
Name and
Principal Position
|
|
|
Fiscal
Year
|
|
|
Salary
|
|
|
Bonus
|
|
|
Stock
Awards
|
|
|
Non-Equity
Incentive Plan
Compensation
|
|
|
All Other
Compensation
|
|
|
Total
|
|
|
John Marotta
|
|
|
2024
|
|
|
$
34,615
|
|
|
|
|
|
$
604,196
|
|
|
|
|
|
|
|
|
$
638,811
|
|
|
President and
Chief Executive Officer
|
|
|
2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Stephen S. Schwartz
|
|
|
2024
|
|
|
$755,366
|
|
|
|
|
|
$4,900,004
|
|
|
$407,659
|
|
|
$61,390
|
|
|
$6,124,419
|
|
|
Former President
and Chief Executive Officer
|
|
|
2023
|
|
|
$750,000
|
|
|
|
|
|
$4,500,037
|
|
|
$289,575
|
|
|
$14,850
|
|
|
$5,554,462
|
|
|
2022
|
|
|
$742,308
|
|
|
|
|
|
$3,500,031
|
|
|
$412,314
|
|
|
$13,725
|
|
|
$4,668,377
|
|
|||
|
Herman Cueto
|
|
|
2024
|
|
|
490,000
|
|
|
$500,000
|
|
|
$2,375,108
|
|
|
$186,200
|
|
|
$14,700
|
|
|
$3,566,008
|
|
|
Former Executive Vice President &
Chief Financial Officer
|
|
|
2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Lindon G. Robertson
|
|
|
2024
|
|
|
$212,019
|
|
|
|
|
|
$
0
|
|
|
$201,923
|
|
|
$13,176
|
|
|
$
427,118
|
|
|
Former Executive Vice President
and Chief Financial Officer
|
|
|
2023
|
|
|
$525,000
|
|
|
|
|
|
$1,500,032
|
|
|
$184,275
|
|
|
$14,850
|
|
|
$2,224,157
|
|
|
2022
|
|
|
$525,000
|
|
|
$200,000
|
|
|
$1,300,041
|
|
|
$264,758
|
|
|
$13,725
|
|
|
$2,303,523
|
|
|||
|
Jason W. Joseph
|
|
|
2024
|
|
|
$454,615
|
|
|
|
|
|
$1,800,060
|
|
|
$140,363
|
|
|
$13,105
|
|
|
$2,408,144
|
|
|
Senior Vice President, General
Counsel/Corporate Secretary
|
|
|
2023
|
|
|
$431,923
|
|
|
|
|
|
$
900,043
|
|
|
$
98,543
|
|
|
$13,661
|
|
|
$1,444,170
|
|
|
2022
|
|
|
$403,846
|
|
|
$100,000
|
|
|
$
750,072
|
|
|
$132,631
|
|
|
$15,268
|
|
|
$1,401,817
|
|
|||
|
Ginger Zhou
|
|
|
2024
|
|
|
$386,539
|
|
|
|
|
|
$1,050,049
|
|
|
$123,383
|
|
|
$13,964
|
|
|
$1,573,935
|
|
|
Senior Vice President &
GM Multiomics
|
|
|
2023
|
|
|
$323,077
|
|
|
|
|
|
$
450,051
|
|
|
$
70,875
|
|
|
$
5,015
|
|
|
$
849,019
|
|
|
2022
|
|
|
$299,231
|
|
|
|
|
|
$
200,103
|
|
|
$
69,804
|
|
|
$
6,734
|
|
|
$
575,872
|
|
|||
|
David Wang
|
|
|
2024
|
|
|
$386,539
|
|
|
|
|
|
$1,050,049
|
|
|
$115,498
|
|
|
$17,239
|
|
|
$1,569.324
|
|
|
Senior Vice President &
GM Sample Management Solutions
|
|
|
2023
|
|
|
$265,885
|
|
|
|
|
|
$
320,859
|
|
|
$
49,025
|
|
|
$10,765
|
|
|
$
646,534
|
|
Customers
Customer name | Ticker |
---|---|
Laboratory Corporation of America Holdings | LH |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|---|---|---|
Robertson Lindon G | - | 117,563 | 0 |
Marotta John | - | 106,296 | 0 |
Joseph Jason | - | 89,006 | 0 |
MARTIN JOSEPH R | - | 85,175 | 0 |
Gray David C | - | 74,868 | 0 |
Zane Ellen M | - | 41,134 | 0 |
Lin Lawrence Y. | - | 37,513 | 0 |
Vacha Robin | - | 31,287 | 0 |
Zhou Ginger | - | 27,916 | 0 |
Vacha Robin | - | 25,788 | 0 |
Cueto Herman | - | 24,604 | 0 |
Wang David Dong | - | 23,974 | 0 |
McLaughlin Erica | - | 16,858 | 0 |
Cueto Herman | - | 14,890 | 0 |
Wang David Dong | - | 9,478 | 0 |
Madaus Martin D | - | 7,405 | 0 |
Crowley Kimberly | - | 7,399 | 0 |
Nova Tina Susan | - | 6,069 | 0 |
Casal Frank | - | 5,789 | 0 |
Hughes Violetta | - | 3,162 | 0 |
Cornog William L | - | 2,255 | 21,755 |